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1 Abstract 
Heme is a prosthetic group of oxygen carrier hemoglobin (Hb). During hemolytic conditions, such as 
sickle cell disease or malaria, heme can be released from cell-free Hb triggering toxicity through 
oxidative reactions. The role of heme in inflammatory processes has been extensively studied but 
remains not completely elucidated. Although activation of TLR4 and downstream inflammatory 
signaling pathways can be triggered by free heme, heme-catabolism through hemoxygenase 1 
(Hmox-1) has been reported to downregulate some components of inflammation and immunity. In 
our laboratory, we could demonstrate that heme does not induce inflammation, suggesting that 
previous reports of pro-inflammatory heme-activity might have been influenced by the difficult 
biophysical properties of purified (protein-free) heme. In contrast, we have identified heme as a 
potent suppressor of inflammation in macrophages. Vascular endothelial cells, as sentinels for 
homeostasis in the blood stream, are among the first cells exposed to cell-free Hb and heme during 
hemolytic diseases. 
 To define the role of heme in the endothelial cell inflammatory response, we performed a number 
of in vitro and in vivo studies. In vitro, heme-treated endothelial cells were stimulated by IL-1β. In 
vivo, heme-treated mice were challenged with lipopolysaccharide (LPS) or with an agonistic anti-
CD40 antibody, which induces a systemic inflammatory response with necrotizing hepatitis. 
In the first part of the present study, we found that heme treatment suppresses the inflammatory 
signaling to IL-1β in human umbilical vein endothelial cells (HUVEC). The most interesting finding 
was that heme challenge suppresses the expression of the adhesion molecule VCAM-1, causing 
decreasing monocyte adhesion.  Along the same line, in vivo heme challenge blunts the endothelial 
response in the context of a LPS-induced systemic inflammatory response syndrome. In a murine 
model of anti-CD40-induced necroinflammatory liver disease, heme-treatment rescues almost 
completely the phenotype of the disease.  
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In the second part of the study, we dissected the possible mechanisms for heme-induced 
hypoinflammation. Using a Hmox-1 knock-out mouse model, we could demonstrate that the 
hypoinflammation was related to heme itself and not to Hmox-1 activity, the main enzyme of heme-
breakdown. Further, we identified Nrf2 activation as a possible candidate for heme-induced hypo-
inflammation in endothelial cells. The heme gene signature of HUVEC is dominated by the 
expression of Nrf2 target genes. The transcription factor Nrf2 is involved in upregulation of anti-
oxidant genes upon increase of oxidative stress in the cell. Recently, Kobayashi et al. described a 
novel property of Nrf2 in suppression of pro-inflammatory NFκB response genes transcription in 
macrophages. 
In conclusion, we demonstrated a novel anti-inflammatory effect of heme on endothelial cells and 
suggested the Nrf2 anti-inflammatory pathway as a possible mechanism involved in this process. 
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2 Abbreviations 
ALT 
APC 
Approx. 
alanine transaminase 
antigen presenting cells 
approximately 
ARE antioxidant response elements 
AST aspartate transaminase 
BSA 
CD40 
bovine serum albumin 
CD40 receptor 
CD40L CD40 ligand 
CD 
CO 
CO2 
Cluster of Differentiation 
Carbon monoxide 
Carbon dioxide 
Ct Cycle threshold 
ddH20  bidestillated water 
EBM Endothelial Basal Medium 
ELISA 
FAM 
Enzyme-linked Immunosorbent Assay  
5(6)-carboxyfluorescein 
FBS fetal bovine serum  
Fig  figure 
FACS 
GSR 
h 
Hb-Hp 
Fluorescent Activated Cell Sorting 
glutathione-disulfide reductase 
hour(s) 
hemoglobin/haptoglobin complex 
H&E staining hematoxylin and eosin staining 
Hmox-1 hemoxygenase 1 
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Hmox-1 ko  hemoxygenase 1 knock-out 
IL-8 human Interleukin-8 
HUVEC Human Umbilical Vein Endothelial Cells 
IL-1  Interleukin-1 
INFγ Interferon γ 
ICAM-1 intercellular adhesion molecule-1  
i.p. intraperitoneal 
keap-1 Kelch-like ECH-associated protein  
LPS 
LuEC 
Lipopolysaccharide 
Lung endothelial cells 
min minutes 
NFκB necrosis factor κB 
NQO1  NAD(P)H dehydrogenase [quinone] 1 
Nrf2 Nuclear factor erythroid-2-related factor 2 
OCR oxygen consumption rate 
PAMPs 
PBMCs  
Pathogen-associated molecular patterns 
Peripheral Blood Mononuclear Cells 
PBS 
PVDF  
RA839 
RBC 
phosphate Buffered Saline 
Polyvinylidene difluoride 
Nrf2 activator 
red blood cell 
rpm  
RT-qPCR 
rounds per minutes 
Real-time quantitative Polymerase chain 
reaction 
s  second 
SA-PE streptavidine-phycoerythrin 
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SD standard deviation 
Scl7a11 Sodium-independent cystine-glutamate 
antiporter 
SOD 
TLR4 
TNFα 
USA 
Superoxide dismutase 
Toll-like receptor 4 
Tumor necrosis factor α 
United States of America 
VCAM-1 Vascular cell adhesion protein-1, CD 106 
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3 Introduction 
3.1 Hemolytic diseases 
Intravascular hemolysis can occur in a variety of medical conditions, which share the common 
problem of accelerated erythrocyte destruction. Hemolytic diseases include congenital hemolytic 
anemias like hereditary spherocytosis or G6PD deficiency, hemoglobinopathies such as sickle cell 
disease or thalassemias, and a broad group of secondary hemolytic diseases including infectious 
diseases like malaria or physical stressors like artificial heart valves or extra-corporal circulation [2]. 
In all these conditions, red blood cells are lysed to an increased degree and release free hemoglobin 
(Hb) into the circulation. 
3.2 Hemoglobin and its functions 
Hb is a highly conserved molecule in diverse species and serves primary as oxygen (O2) carrier and 
carbon dioxide (CO2) remover in the circulation to secure efficient respiration. To fulfill this function, 
Hb needs to be inside of the erythrocytes. When erythrocytes are destroyed under physiological 
conditions, the released Hb enters the blood stream and is bound to its scavenger protein 
haptoglobin (Hp). In intravascular hemolysis, Hp can be quickly depleted and Hb can reveal its 
adverse effects. Firstly, Hb extravasates and causes nitric oxide (NO) depletion in vascular wall, 
leading to vasoconstriction and hence pulmonary and blood pressure increase, a major factor 
regarding the development of cardiovascular events in hemolytic diseases [3, 4]. Secondly, free Hb 
reacts with lipids or proteins in the blood stream and leads to the development of radical oxygen 
species (ROS) or oxidizes to Met-Hb. The oxidation of Hb leads to conformational changes in globin 
chains causing the release of its prosthetic group heme in the blood stream [5]. 
11 
 
3.3 Heme and its structure 
Heme belongs to a family of porphyrins, which play a crucial role in many essential processes like 
redox reactions or oxygen transport in almost all living organisms. Heme b, a prosthetic group of 
human Hb, consists of protoporphyrin IX with one central iron (Fe2+) atom, which acts as acceptor 
and donator of oxygen (O2) molecule and is therefore one of the most central molecules in human 
body. The oxygen carrier protein Hb consists of two dimers of α- and β-globin chains (α1β1 and 
α2β2) and four heme b prosthetic groups. Each heme b consists of four pyrrole rings, sharing a 
common central Fe2+ atom (Figure 1). The unique constellation of heme groups and globin chains 
allows cooperative binding and release of O2 with increasing affinity from the first to the fourth O2 
binding, a main principle of oxygen transport in human body [1].  
 
 
Figure 1: Oxygenated (Fe2+) form of heme [1] 
A-D: four pyrrole rings, Fe(II): central iron atom with binding to O2 and protein chain 
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3.4 Heme and its functions 
Because of its high oxidation potential, free heme contributes to oxidative stress by production of 
ROS and is thus thought to play a key role in Hb toxicity [6]. However, an elaborate scavenging 
system is protecting the vascular system from heme toxicity. When free heme enters plasma, it is 
bound with high affinity to its endogenous scavenger protein hemopexin or other hemoproteins and 
then degraded predominantly in the liver by the enzyme hemoxygenase-1 (Hmox-1) [5]. The anti-
oxidative and anti-inflammatory protein Hmox-1 is the rate-limiting enzyme in heme breakdown 
and is present in all cell types. Hmox-1 catabolizes heme degradation to its products carbon 
monoxide (CO), biliverdin and iron, which are known for their anti-inflammatory properties [7, 8].  
Besides its oxygen carrier function, heme acts as signaling molecule in extra- and intracellular 
responses by binding to several receptors, transcription factors and enzymes. Notably, heme is 
known to activate Toll-like receptor 4 (TLR4) and its downstream necrosis factor κB (NFκB) 
inflammatory signaling [9-11]. However, the question whether free heme is pro- or anti-
inflammatory is still subject of debate. In our laboratory, we have demonstrated that heme does not 
induce inflammation [12]. This contradictory observation may be explained by the difficult 
biophysical properties of heme. Moreover, heme as a strongly lipophilic molecule is almost insoluble 
in aqueous environment and will under physiological conditions, as soon as released form Hb, 
immediately bind to other serum hemoproteins like hemopexin, or to lipoproteins, making unlikely 
that significant quantities of free monomeric heme can be present in the plasma [13]. Recent data 
from our laboratory identified heme as a potent suppressor of inflammation in macrophages 
(manuscript in preparation).   
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3.5 Endothelial cells and their function 
Endothelial cells build the inner layer of blood vessels and play a key role in adjustment reactions of 
vascular system to changes in blood homeostasis, because of their crucial position between blood 
and surrounding tissue. The main functions of endothelial cells include their barrier function and 
their function as vasomotor regulators and initiators of the coagulation cascade after vascular injury 
[14]. Dysregulation of this delicate system can lead to thrombosis formation, thrombolysis 
impairment, vascular leakage and edema [14]. Furthermore, endothelial cells are capable to identify 
danger signals and hence to initiate immune system activation [14-16].  
3.6 Inflammatory response in endothelial cells 
Activation of endothelial cells and their role as sentinel cells in the bloodstream is a crucial 
mechanism for the immune system to fight infections. Endothelial cells show fast inflammatory 
response to presence of bacteria, viruses and foreign substances in blood stream. Different 
receptors on endothelial surface are involved in response to diverse pro-inflammatory stimuli. The 
direct activation of endothelial inflammatory response by pathogens in the bloodstream occurs via 
different TLR signaling [14]. For example, lipopolysaccharide (LPS), an archetypical representative 
of pro-inflammatory stimuli called Pathogen-Associated Molecular Patterns (PAMPs), is very 
efficiently recognized by a variety of cells including endothelial cells via their surface receptor TLR4 
[17]. LPS/TLR4 binding initiates pro-inflammatory NFκB pathway activation, inducing a robust 
release of IL-6 and IL-8 [15] and upregulation of adhesion molecules such as Vascular Cell Adhesion 
Protein 1 (VCAM-1), Intercellular Adhesion Molecule 1 (ICAM-1) or E-selectin to facilitate leucocyte 
adherence and promote transendothelial migration [14, 16, 18]. Release of the chemokine IL-8 from 
activated endothelial cells acts as a strong promotor of monocyte adhesion to endothelial cells after 
cytokine activation [19].  Transcription factor NFκB is a central element in cellular inflammatory 
response, which regulates transcriptional upregulation of pro-inflammatory cytokines, chemokines 
and adhesion molecules [15].  A very common indirect activation of endothelial cells by LPS occurs 
via activation of innate immune cells, especially monocytes and granulocytes, and their release of 
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potent NFκB pathway chemokines TNFα and IL-1β, which trigger activation of endothelial cell 
inflammatory response [15, 20]. 
3.7 CD40 ligand-CD40 receptor signaling 
Besides the classical LPS-induced, TLR4-dependent endothelial activation, CD40 receptor (CD40) 
represents a different pro-inflammatory signaling receptor. Yet, both receptors share a common  
NFkB end pathway [21].   
CD40/CD40 ligand (CD40L) signaling is very well established in the context of adaptive immune 
response initiation as a secondary signal. The primary signal through activated antigen receptors on 
T- and B-lymphocytes is needed to start adaptive immune response, but rigorous control of this 
process is essential and so secondary signals from a variety of co-stimulatory receptors are involved 
in its regulation. Hereby, one of the most important co-stimulatory receptors is the CD40. CD40 is 
expressed on different antigen presenting cells (APC), including B-cells, monocytes and 
macrophages, but can also be found on endothelial, epithelial and some tumor cells, where it acts as 
a primary inflammatory receptor for innate immune response [22].  
Endogenous CD40L is expressed in the organism mainly on activated CD4+ T-cells and binds to 
CD40 on the APC [23]. CD40/CD40L binding enhances cellular innate immune responses like 
chemokine and cytokine release from macrophages, or expression of adhesion molecules on 
endothelial cells. In the cells of innate immunity, CD40/CD40L binding initiates their inflammatory 
mediator production and release. Imbalance in this interaction may lead to development of 
autoimmune or inflammatory diseases [23]. Activation of CD40 was recently shown to play a central 
role in inflammatory liver disease including allograft rejection and viral hepatitis [21].  
A model of necroinflammatory liver disease induced by the application of an anti-CD40 antibody, 
which mimics the effect of endogenous CD40L, was previously described and studied in the mouse 
[24, 25]. Anti-CD40L-dependent macrophage activation, leading to elevation of inflammatory 
cytokines like tumor necrosis factor-α (TNFα), was reported in this context [21].  
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3.8 Nrf2 and Nrf2/keap-1 pathway 
Nuclear factor erythroid-2-related factor 2 (Nrf2) is the principal transcription factor that regulates 
expression of approximately 200 antioxidant genes upon oxidative or xenobiotic stress [26] [27]. 
Nrf2 dependent upregulation of anti-oxidant gene transcription leads to enhanced elimination of 
reactive oxygen species (ROS) in the cell.   
In an unstressed cell, Nrf2 resides in the cytoplasm bound to its inhibitory protein Kelch-like ECH-
associated protein (keap-1) and is degraded by E3 ubiquitin ligase in lysosomes. Upon activation 
through increased ROS, keap-1 dissociates from Nrf2 and the transcription factor is free to enter the 
nucleus and bind to the antioxidant response elements (ARE)-regions and start the transcription of 
its target genes [28-30]. The typical Nrf2 transcription modulation includes upregulation of ROS 
degradation enzymes like superoxide dismutase (SOD) or glutathione-disulfide reductase (GSR) and 
other typical Nrf2 gene targets like Hmox-1 hemoxygenase 1 (Hmox-1) or NAD(P)H dehydrogenase 
[quinone] 1 (NQO1) [31]. 
In the recent years, the role of Nrf2 in anti-inflammation drew increased attention in the research 
community. Nrf2 activation has been linked to transcriptional suppression of NFkB-dependent pro-
inflammatory cytokines [9, 18], and this mechanism was connected to the Nrf2-dependent anti-
oxidative upregulation of Hmox-1 [30], but the exact mechanism could not yet been completely 
unraveled.  
Recently, Kobayashi et al. described Nrf2-dependent transcriptional inhibition of proinflammatory 
cytokine genes in macrophages, which appears to be independent of the classical Nrf2 anti-
oxidative pathway driven by ROS [29]. They demonstrated that pro-inflammatory cytokines IL-1β 
and IL-6 have no ARE regions and no Nrf2 transcription factor binding sites in their promotor regions 
or in the proximity of their genes, hence an alternative Nrf2-dependent transcriptional regulation 
must exist. Further, they confirmed that Nrf2 suppresses upregulation of NFkB-dependent pro-
inflammatory pathway, but they could show that NFkB binding to the regulatory regions of its 
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response genes is not disturbed [29]. In summary, the anti-inflammatory inhibiting effect on 
transcription of NfkB pathway genes and the anti-oxidative upregulatory effect on antioxidant 
genes may be two separate effects of Nrf2.  
The importance of Nrf2 in the cellular anti-inflammatory processes was described in variety of 
diseases like multiple sclerosis (or its murine pendant experimental autoimmune 
encephalomyelitis), diabetes or autoimmunity [32-34]. Interestingly, the Nrf2 inducer 
Dimethylfumarate (Tecfidera®) has recently been established as a novel drug in multiple sclerosis 
therapy and is evaluated for use as an anti-inflammatory drug in other autoimmune diseases. 
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3.9 Hypothesis and aims 
The overall aim of this project is to characterize the anti-inflammatory effects of heme and dissect 
its mechanistic pathway on endothelial cells.   
Hypothesis  
Heme treatment suppresses inflammatory responses of endothelial cells to typical inflammatory 
agonists in vitro and in vivo. 
Aim 1 
To characterize the effect of heme on endothelial cell activation and inflammation in human 
endothelial cells in vitro and in mouse models in vivo  
Aim 2 
Dissect the mechanistic pathway involved in the suppressive effect of heme on inflammatory 
responses of endothelial cells.  
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4 Material and Methods 
4.1 Cell culture conditions and experimental treatment on HUVEC 
Human umbilical vein endothelial cells (HUVEC, Lonza, Walkersville MD, USA) were cultured on rat 
tail collagen type I (Corning, Corning NY, USA) coated plates in Endothelial basal medium (EBM, 
Lonza) enriched with EGM SingleQuots (Lonza) containing human epidermal growth factor (hEGF), 
hydrocortisone, Gentamycin-1000, 2% fetal bovine serum (FBS) and ascorbic acid according to the 
supplement list given by the manufacturer.  Cryopreserved cells were expanded until passage 3 and 
frozen  back at -80°C with a supplement of DMSO as a cryopreservant. For experiments, cells were 
subsequently put back in the culture and used from passage 5 to 6. HUVEC were cultured under 
standard conditions at 37°C with 80% humidity under 5% CO2. Culture medium was changed every 
48h. The experimental treatments were conducted on confluent layer of HUVEC. The standard 
treatment consisted of heme-albumin treatment in concentrations ranging from 0 to 160µM in the 
standard culture media for 4h followed by treatment with human inflammatory agonist Interleukin-
1β (IL-1) at a standard working concentration of 100U/ml for 4h. After 8h of treatment, the cells 
were harvested for future analysis. Modifications to this standard treatment protocol are indicated 
in the corresponding method sections.  
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4.2 Heme-albumin preparation 
A 4mM heme-albumin solution was prepared as follows: 65mg Hemin (Frontier Scientific, Inc., 
Logan, UT, USA) was dissolved in 10ml 100mM NaOH in a water bath at 37°C. After 10 min, 10ml of 
20% human serum albumin (CSL Behring AG, Bern, Switzerland) were added and incubated at 37°C 
for 1h to enable the formation of heme-albumin. Next, thepH of the solution was adjusted to 7.45 
using ortho-phosphoric acid and the solution was sterile-filtered (0.22µm). The 4mM heme-albumin 
solution was used within 24h for the experiments, diluted in the culture medium to the working 
concentrations indicated, or for i.p. injections in the mice.  
4.3 RNA Isolation and quantitative Real time polymerase chain reaction 
4.3.1 RNA Isolation 
RNA was isolated using QIAgen RNAeasy Mini Kit (QIAgen, Hilden, Germany) according to the 
manufacturer’s instructions including DNA digestion step. Shortly, confluent HUVEC on 6-well 
culture plates were lysed using RLT-Lysis buffer (QIAgen, Basel, Switzerland) containing 1% 2-
Mercaptoethanol, collected to 1.5ml tubes and stored at -80°C. RNA was isolated and the quality 
and quantity was determined spectrophotometrically on the NanoDrop ND-1000® instrument. Total 
RNA was reverse transcribed to cDNA with TaqMan Reverse Transcription reagents (Applied 
Biosystems, Carlsbad CA, USA) on a Mastercycler gradient (Vaudaux-Eppendorf, Schoenenbuch, 
Switzerland) with the following cycle settings: 25°C for 10 minutes, 48°C for 30min and 95°C for 
5min, followed by holding step at 4°C.  The obtained cDNA was spectrophotometrically quantified 
and diluted to an approximate concentration of 300 ng/µl with RNAse free water. 
4.3.2 RT-qPCR 
Real-Time quantitative Polymerase Chain Reaction (RT-qPCR) was performed on the AB 7500 FAST-
Real-Time PCR System (Applied Biosystems, Carlsbad CA, USA) using 2µl of cDNA, 10µl of TaqMan 
FAST Universal PCR Mastermix (2x) (Applied Biosystems, Carlsbad CA, USA), 7µl RNAse-free water, 
and 1µl primer following the TaqMan FAST Run method, which doesn’t require an activation step 
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due to hot-start DNA polymerase. The RT-qPCR profile contains an initial denaturation step (20s at 
95°C), followed by 40 cycles of alternate denaturation (3s at 95°C) and annealing/elongation (30s at 
60°C).  
Alternatively, the SYBR green qPCR method with 10 µl PowerSYBR green PCR Mastermix (Applied 
Biosystems, Carlsbad CA, USA), 7.2µl RNA-free water, 0.8µl primer mix and 2µl cDNA was applied 
on the same instrument with the following temperature profile: 20s at 50°C,10min at 95°C, 40 cycles 
of alternate denaturation (15s at 95°C) and annealing/elongation (60s at 60°C). Subsequently, the 
melting curve was determined and checked for unspecific amplification and primer-dimer building 
after each qPCR run.  
Data were calculated as fold change in mRNA levels and normalized to the Ct (cycle threshold) 
values of the unregulated reference gene HPRT using the ΔΔCt method. 
4.3.3 Primer design 
Primers for the SYBR green method were designed with the Universal Probe Library Assay Design 
Center (Roche Lifescience software) and checked for quality with OligoAnalyzer3.1 (IIntegrated DNA 
Technologies) including matching temperature of forward and reverse primer, formation of primer 
dimers or hairpin structures. Selected primer pairs were ordered from Microsynth (Microsynth AG, 
Balgach, Switzerland). Human primers used for SYBR green amplification are listed in table 1.  FAM 
(5(6)-carboxyfluorescein) primers for human and mouse genes were ordered online from Thermo 
Fisher (Thermo Fisher Scientific, Waltham MA, USA) and are listed in table 2 and 3.  
Table 1: Primers to human genes for use in SYBR Green amplification 
Gene (5' - 3') (3' - 5') 
HPRT TGACCTTGATTTATTTTGCAT CGAGCAAGACGTTCAGTCCT 
E-Selectin TGGCAATGAAAAATTCTCAGTCA TCAAGGCTAGAGCAGCTTTGG 
IL-8 CCTTTCCACCCCAAATTTATCA TGGTCCACTCTCAATCACTCTCAG 
Hmox-1 AGGCCAAGACTGCGTTCCT GGTGTCATGGGTCAGCAGC 
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NQO1 GGGATCCACGGGGACATGAATG ATTTGAATTCGGGCGTCTGCTG 
SLC7A11 CCATGAACGGTGGTGTGTT GACCCTCTCGAGACGCAAC 
PTGS2 CTTCACGCATCAGTTTTTCAAG TCACCGTAAATATGATTTAAGTCCAC 
VCAM-1 TGCACAGTGACTTGTGGACAT CCACTCATCTCGATTTCTGGA 
GSR ATGATCAGCACCAACTGCAC CGACAAAGTCTTTTTAACCTCCTT 
 
Table 2: FAM Primers to human genes 
Gene Order Number 
HPRT Hs02800695_m1 
ICAM1 Hs00164932_m1 
E-Selectin Hs00950401_m1 
Hmox-1 Hs01110250_m1 
VCAM-1 Hs01003372_m1 
NQO1 Hs00168547_m1 
SLC7A11 Hs00921938_m1 
 
Table 3: FAM Primers to murine genes 
Gene Order Number 
HPRT Mm01545399_m1 
ICAM1 Mm00516023_m1 
Hmox-1 Mm00516005_m1 
VCAM-1 Mm01320970_m1 
NQO1 Mm01253561_m1 
SLC7A11 Mm00442530_m1 
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4.4 VCAM-1 In-Cell Western Immunofluorescent Assay  
In-Cell Western Immunofluorescent Assay combines the techniques of Western Blotting and 
Enzyme-linked Immunosorbent Assay (ELISA) and enables measurement of cell surface protein 
levels directly in fixed cultured cells [35][36].  
Cellular VCAM-1 was measured using the in cell method as follows: HUVEC were cultured directly in 
a 96-well plate precoated with rat tail collagen type I until they reached over 90% confluency. Cells 
were pretreated 4h with 0, 80 or 160µM heme-albumin, subsequently stimulated with standard 
concentration of 100U/ml IL-1 for additional 4h. Supernatants were collected and cells were 
immediately fixed with 3.7% formaldehyde directly in the plate for 20 min. The cells were washed 
and permeabilized with 0.1% Triton-X-PBS solution and then blocked with LI-COR Odyssey Blocking 
Buffer (LI-COR Biotechnology, Lincoln NE, USA). Primary goat-anti-hVCAM-1 (R&D Systems, Inc., 
Minneapolis MN, USA) was diluted 1:8000 in LI-COR Odyssey Blocking Buffer and added to the cells 
for 1h. After another washing step, the cells were incubated with the secondary antibody donkey 
anti-goat IRDye® 800CW  1 µg/ml (LI-COR) and, at the same time, with the far-red fluorescent live-
cell permanent DNA Dye DRAQ5 TM (0.5 µM; Cell Signaling Technology Inc., Danvers MA, USA) for 
1h. After final washing, the immunofluorescence was immediately measured with an Odyssey 
infrared imager (LI-COR) at 700nm for the red live-cell DNA stain DRAG5 TM and at 800nm for the 
VCAM-1 green signal, simultaneously. The data were analyzed with Odyssey software (LI-COR). 
4.5 IL-8 Immunoassay 
Bio-Plex Pro® Assay technology works similar to a combination of sandwich enzyme-linked 
immunosorbent assay (ELISA) and FACS analysis [37]. Due to a special detection system similar to 
flow cytometry (FACS), this technology enables to detect multiple molecules of interest and 
determine their concentrations in one experimental plate.  
Bio-Plex Pro® Assay (Bio-Rad Laboratories AG, Cressier, Switzerland) was carried out exactly 
according to manufacturer’s instructions. Shortly, culture supernatants from the above described 
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VCAM-1 In cell Assay were diluted 1:4 in assay buffer and then added to 96-well plates containing 
fluorescent dyed beads coupled to human IL-8-antibody. In second step, streptavidine-
phycoerythrin (SA-PE) marked detection complex was added and after an incubation and a washing 
step, the plates were directly read on a Bio-Plex 200 system (Bio-Rad) and analyzed using Bio-Plex 
Data Pro software (Bio-Rad).  
4.6 Monocyte adhesion Assay 
HUVEC were cultured in 96-well plates to >90% confluency. The confluent cells were prestimulated 
with heme-albumin (0,80,160µM) for 4h and then treated with human IL-1β (100U/ml) for 1h. 
Human monocytes were isolated from peripheral blood of healthy volunteers obtained from the 
Swiss Red Cross Blood Bank according to our monocyte isolation protocol as described previously 
[38, 39].  The human blood-derived monocytes were fluorescence labelled with Calcein (R&D 
Systems) and then prestimulated for 1h with LPS (1µg/ml). In the next step, 40’000 activated 
monocytes were added per well of confluent HUVECs and incubated for 30min at 37°C. Then, the 
plates were washed with PBS to remove non-adherent cells. Fluorescence of adherent monocytes 
was quantified at 485nm (excitation) and 520nm (emission) with the Tecan infinite M200 pro 
instrument and Tecan i-control I.II software (Tecan Group Ltd., Männedorf, Switzerland).[40] 
4.7 Electric cell impedance measurement 
ECIS® (Electric Cell-substrate Impedance Sensing) is a real-time method, which records changes in 
trans-endothelial electric resistance of endothelial monolayer under standardized conditions 
continuously over time. Therefore, cell growth and changes in barrier function and cell permeability 
of endothelial cells in response to experimental treatments can be studied by determination of 
impedance over time. Impedance is the equivalent of resistance in settings using alternating instead 
of direct current. We recorded real-time endothelial barrier function changes using ECIS Zθ system 
and ECIS Software v.1.2.70.1 PC (Applied BioPhysics, Troy NY, USA) according to our protocol as 
described in [41]. 
24 
 
Shortly, ECIS 8W10E+ chamber arrays were equilibrated with DMEM (Gibco, Carlsbad CA, USA) 
medium without serum for 4h and coated with rat tail collagen type I (Corning) for 2 h. In a next 
step, 70’000 HUVEC in standard culture medium were added to each chamber well, put in incubator 
(37°C, 80% humidity, 5% CO2), and the experiment was started immediately. Our impedance 
measurement in ohms (Ω) was run at a frequency of 16kHz in ECIS 8W10E+ arrays containing 40 
electrodes per each of its 8 wells. The cell monolayer impedance is at the same time measured at 40 
different locations in each well and averaged to mean impedance for every time point. The cells 
were cultured until a dense monolayer of confluent cells was reached. During the growth of the cells 
on the gold electrodes, a steadily increase of impedance is observed. As the cells come to 
confluency, the impedance reaches a stable plateau and the experimental treatments can be 
started.[4] HUVEC were treated with 0, 80,160 and 320µM heme-albumin in culture medium and the 
changes in impedance over time were recorded for the following 12h. 
4.8 Extracellular Flux Assay 
Extracellular Flux Assay is a noninvasive method to measure effects of experimental treatments on 
mitochondrial function on living cells.[42]. During the measurement 3 different compounds, namely 
oligomycin, FCCP and rotenone/antimycin A are injected into the experimental wells. These 
compounds are selective inhibitors of mitochondrial complexes V (oligomycin) and complexes 
I/III(rotenone/antimycin A), and FCCP is a disruptor of H+-gradient of the mitochondrial membrane. 
With selective inhibition of these complexes, ATP-linked respiration, maximal respiration, and 
nonmitochondrial respiration of the cells, are determined (figure 2) [43]. As read-outs for 
mitochondrial respiration and glycolysis rate, changes in maximal oxygen consumption rate (OCR) 
and extracellular acidification rate (ECAR) are measured after addition of experimental treatments. 
Moreover, changes in mitochondrial function of the cells are sensitive markers for cell survival and 
cell death.   
We used Agilent Seahorse XFp Cell Mito Stress Test Kit (Agilent Technologies, Santa Clara CA, USA) 
following strictly the protocol given by the manufacturer. In short, we seeded 40’000 HUVEC 
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cells/well directly on XFp cell culture miniplates (Agilent Technologies) and cultured them for 24h at 
37°C under standard conditions. After 24h half of the medium was removed and replaced by 
experimental treatment medium with different concentrations of heme-albumin (0, 80,160µM) for 
6h. Untreated samples and blank wells in duplicates were included as controls. After a washing step 
and 1h incubation without treatment, the mitochondrial function was determined running the Mito 
stress test seahorse program on the Seahorse XFp Analyzer (Agilent Technologies). Data show 
the difference in OCR and ECAR over time between control and heme-albumin treated 
samples. 
 
Figure 2: Principle of mitochondrial respiration measurement with Agilent Seahorse XFp Cell 
Mito Stress Test Kit [44] 
4.9 Nrf2 Translocation Assay 
HUVEC were cultured in 150mm × 25mm rat tail collagen precoated dishes as described before and 
culture medium was changed 24h before the experiment. Confluent HUVEC were treated with 
0,80,160µM heme-albumin or 20µM RA839 (commercial Nrf2 activator) for 6h and cytoplasmic and 
nuclear protein fractions were subsequently isolated with Nuclear Extract Kit (active motif, Carlsbad 
CA, USA) according to the manufacturer’s instructions. Briefly, the cells were washed with ice-cold 
PBS containing phosphatase inhibitor and removed from the plates by gently scraping. After a 
centrifugation step at 200xg for 5min at 4°C, the cell pellet was resuspended in 1xHypotonic Buffer 
and incubated for 15 min on ice. Then, detergent was added to the solution and the cell lysates were 
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vortexed for 10s at the highest setting. Efficiency of the lysis was controlled by comparison of 10µl 
before- and after-lysis samples by phase-contrast microscopy. To separate the nuclear fraction, 
samples were centrifuged at high rate (14000xg-30s-4°C) and supernatants containing cytoplasmic 
fractions were transferred to separate tubes and stored at -80°C. 
The remaining nuclear pellets were resuspended in complete lysis buffer. 2.5µl detergent were 
added to solubilize membrane-associated nuclear proteins and the samples were mixed by 
vortexing at highest rate for 30s and incubated for 30min on a rocking platform at 150rpm and 4°C. 
After another vortexing and centrifugation step (14000xg-10min-4°C), supernatants containing 
nuclear fractions were transferred to a new tube and stored at -80°C. 
Protein concentrations of both cytoplasmatic and nucleic fractions were measured with Bradford 
Assay. Complete Lysis Buffer 1:50 dilution was used as a blank. 
Samples were mixed with 2x Laemmli buffer, heated at 95°C for 5min and then separated on a 
polyacrylamide gel (Criterion™ TGX Stain-Free™ Precast Gel, BioRad, Hercules CA, USA) under 
following running conditions: 200V, 35-55mA, 35min. Precision Plus Protein All Blue Prestained 
Protein Standard (Bio-Rad) was run simultaneously as a control. After electrophoresis, proteins were 
transferred to a PVDF (Polyvinylidene difluoride) membrane (Thermo Scientific, USA) in a wet 
electrotransfer chamber (Criterion™ Blotter, BioRad) under constant voltage (100V) for 30min.  
Thereafter, the membrane was blocked with 10% goat serum and 1% bovine serum albumin for 1h 
and then cut at 75kb. The upper part of the membrane was incubated with primary antibody against 
human Nrf2 (Active motif), diluted 1:1000 in 1%Tween-PBS at 4°C overnight. The lower part of the 
membrane was incubated at 4°C overnight in primary antibody against human β-actin (1:2000 
dilution in 1% Tween-PBS, Sigma) used as a loading control. 
After washing with 1%Tween-PBS, the upper part of the membrane was incubated in anti-rabbit-
horseradish peroxidase antibody (1:4000 dilution), and the lower part in Alexa Fluor® 488 goat anti-
mouse IgG at room temperature for 1h. 
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After final washing, chemiluminescence detection for the upper part of the membrane was 
performed using Supersignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific) and 
the membrane was immediately analyzed on a ChemiDoc MP Imaging system with Image Lab 5.2.1 
software (Bio-Rad). The lower part of the membrane was analyzed in the ChemiDoc MP Imaging 
system in fluorescence detection mode, detecting immunofluorescence at 488nm.  
4.10 In vivo experiment heme ± LPS in mice 
We designed an in vivo experimental setup using wild type and Hmox-1 knockout mice to elucidate 
the role of heme on endothelial cell activation in vivo and the role of Hmox-1 in this process. In the 
UBC cre-ERT2 +/- Hmox-1 flox/flox mouse model, Cre recombinase is fused to estrogen receptor 
(ER) ligand-binding domain under the ubiquitary UBC promotor and is activated at a specific time 
point by addition of exogenous estrogen receptor ligand (in our case Tamoxifen) to the model 
system. Activated Cre recombinase cuts the DNA at lox marked sites, which flank the Hmox-1 
alleles, and cause a removal of Hmox-1 from the DNA.  
Wild-type C57BL/6J animals used in our experiments were obtained from Charles River (Wilmington, 
MA, USA). UBC cre-ERT2 +/- Hmox-1 flox/flox animals were bred in our facility, genotyped at birth 
and then at the age of 4 weeks treated on 5 following days with tamoxifen gavage (Sigma-Aldrich; 
200g/kg body weight) to activate cre recombinase and obtain hmox1 knockout animals. The animals 
were re-genotyped 4 weeks after tamoxifen treatment and Hmox-1 knock-out animals were 
subsequently used within 1 week for the experiment. The animals were treated overnight with 
heme-albumin 100µmol/kg body weight (wild-type animals) or 50 µmol/kg body weight (Hmox-1 
knockout animals) intraperitonealy (i.p.), following 4h treatment with LPS 0.5mg/kg body weight 
i.p. as an TLR4 agonist.  The protocol of our experiment was proved by the Veterinary Office of the 
canton of Zurich under the license number 078/2016. All animals were housed at the Laboratory 
Animal Services Center (LASC) of the University of Zurich and were treated according to guidelines 
of the Swiss Federal Veterinary Office. 
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4.11 Murine lung cell isolation  
Lung cells from heme-albumin and/or LPS treated mice were isolated for further analysis by flow 
cytometry and RT-qPCR. The mice were sacrificed by cervical dislocation. Lungs were flushed with 
PBS by right-ventricle perfusion of the beating heart to eliminate blood cells from the lung 
circulation. Lung lobes were removed separately, washed with ice-cold PBS and lung digestion was 
promptly started using the Lung Dissociation Kit (Miltenyi Biotec, Bergisch Gladbach, Germany) 
according to manufacturer’s instructions. Lung lobes were put into digestion enzyme mix and placed 
in C Tubes (Miltenyi Biotec) on gentle MACS™ Octo Dissociator with Heaters (Miltenyi Biotec) for 30 
min following the 37°C_LDK_1 program. After termination of the program, cell suspensions were 
filtered (70µm), washed with 2.5ml Buffer S and centrifuged at 300xg for 10min. Supernatant was 
discarded and cells were resuspended in 2 ml FACS Buffer containing 0.1%BSA. Lung cells were 
counted on a NucleoCounter® using a 10µl aliquot and processed immediately for further use in flow 
cytometry or FACS sorting.  
4.12 Flow cytometry and FACS sorting of murine lung endothelial cells 
4.12.1 Flow cytometry 
Flow cytometry experiments were performed to characterize the lung endothelial cell (LuEC) 
population. We defined our population as a CD45 negative, CD31 and CD102 positive population[45, 
46]. The antibodies used for our experiments are listed in Table 4.  
Murine lung single cells in FACS Buffer were equally distributed to 6 FACS tubes per sample to 
obtain single stained, fully stained and unstained sample for each probe and centrifuged at 1250 rpm 
for 5 min. The supernatant was discarded, cells were resuspended in FACS buffer containing 
antibodies at concentrations of 1-2µg/ml and incubated in dark on ice for 30min. After two washing 
and centrifugation steps, the cells were resuspended in 300µl FACS buffer and analyzed on a LSRII 
Fortessa flow cytometer using FACS DIVA Software (BD Biosciences, Franklin Lakes NJ, USA). Gates 
were set for exclusion of cell fragments, doublets, dead cells and CD45 positive cells. The CD45 
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negative cells were divided by CD31/CD102 positivity and the double positive population was 
defined as the lung endothelial cell population of interest[45, 46] (figure 3). Compensation with 
single stainings were performed and at least 100 000 events were recorded. Final data analysis was 
performed with FlowJo 10.4.1 software (FlowJo, LLC, Ashland OR, USA).  
 
Figure 3: Gating strategy of heme ±LPS in vivo treated murine lung endothelial cells (LuEC) 
All in vivo samples for FACS Sorting were labelled with following fluorescent antibodies: LIVE-DEAD 
IR, CD45 (=Protein tyrosine phosphatase, receptor type, C)-, CD31(=PECAM-1)- and CD102(=ICAM-
2)- antibody. CD45 negative, CD31 and CD102 positive populations were used for further analysis. 
 
Table 4: Antibodies used for flow cytometry 
Gene Order Number 
Antibody Cluster of 
differentiation 
Label Company 
LIVE/DEAD   Near IR (APC-Cy7) Invitrogen 
anti-mouse CD45.2 CD45/ PTPRC Pacific Blue Bio Legend 
rat-anti-mouse CD102 CD102/ICAM2 FITC BD Biosciences 
rat-anti-mouse CD31 CD31/PECAM1 APC BD Biosciences 
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4.12.2 Fluorescent Activated Cell Sorting 
Fluorescent Activated Cell Sorting (FACS Sorting) was applied to obtain lung endothelial cells for 
further analysis by RT-qPCR. Murine lung single cell suspension was prepared and stained as 
described above for FACS and sorted on the BD FACSAria™ III instrument (BD Biosciences) with 
gate settings implemented for the flow cytometry analysis. 70’000 CD45 negative, CD31/CD102 
positive cells were sorted in a 1.5ml microtube containing 150µl RLT Lysis Buffer (QIAgen). 1% 2-
Mercaptoethanol was added directly after the sorting and the cell lysate was kept at -80°C for RNA 
Isolation.  
4.12.3 RNA Isolation and RT-qPCR from murine lung endothelial cells 
RNA from FACS sorted lung endothelial cells was isolated using RNeasy® Micro Kit (QIAgen) 
according to the manufacturer’s protocol. 7.7µl of purified RNA were reverse transcribed to cDNA 
with TaqMan Reverse Transcription reagents (Applied Biosystems, Carlsbad CA, USA) as described 
above. cDNA was spectrophotometrically quantified and checked for quality and then diluted with 
DNAse free water to approximate 300 ng/µl. FAM qPCR with TaqMan FAST Universal PCR 
Mastermix was performed using 2µl of diluted cDNA. Change of VCAM-1 expression was normalized 
to unregulated reference gene HPRT and displayed as 𝑙𝑙𝑙𝑙𝑙𝑙2−∆𝐶𝐶𝐶𝐶. FAM-labeled primers used in this 
experiment are listed in Table 3. 
4.13 In vivo experiment for heme ± anti-CD40 in mice 
We used an in vivo model of agonistic anti-CD40 induced murine necroinflammatory liver disease as 
a TLR4-independent NFκB agonist [24]. Wild-type C57BL/6J animals were obtained from Charles 
River (Wilmington, MA, USA) and further bred in the LASC animal facility under standard conditions 
as described above. The animals were divided into 4 treatment groups and received treatment with 
either heme-albumin (protocol described in heme-albumin preparation) or anti-CD40 (anti-mouse 
CD40; BioXCell, West Lebanon, USA) as follows: Control animals remained untreated; the heme-
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albumin group was treated with singular i.p. injections of heme-albumin (70µM/kg body weight). 
The third group was pretreated with heme-albumin i.p. (70µM/kg body weight) for 4h and then 
received i.p. injections of anti-CD40 (10mg/kg body weight). The fourth group received the same 
dose of anti-CD40 i.p at the same time point as the previous group. The animals were sacrificed 24h 
after anti-CD40 injection for blood collection, or 48h after anti-CD40 administration for liver 
collection. The experimental protocol was approved by Veterinary Office of the Canton of Zurich 
under the license number 014/2017. 
4.13.1 Liver collection for histology and H&E staining 
Liver lobes from mice were removed, rinsed in PBS and placed in 10% formalin solution (Sigma-
Aldrich, St.Louis, USA) for fixation. The organs were transferred to 70% ethanol after 48h. Paraffin 
embedding and microtome sectioning (3µm) were done by the Institute of Veterinary Pathology, 
Vetsuisse faculty, University of Zurich. The slides were stained with H&E staining using hematoxylin 
(hematoxylin solution, Harris modified, Sigma-Aldrich) and eosin solution (eosin y solution, 
aqueous, Sigma-Aldrich) according to standard manufacturer’s protocol. Histology images were 
obtained using Zeiss AxioObserver Z1 microscope with AxioCam MRm and 10x objective and 
scanned with ZEN software (all Carl Zeiss AG, Feldbach, Switzerland). 
4.13.2 Blood collection and liver enzyme measurement 
Terminal blood collection through heart punction of anesthetized mice was performed and blood 
was immediately transferred to heparin coated 0.5ml tubes. To obtain plasma, the heparin tubes 
were centrifuged for 10min at 3000xg at 4°C. The plasma was transferred to 1.5ml Eppendorf tubes 
and 32µl were used immediately for liver enzyme measurement using a Reflotron Plus clinical 
chemistry system (Roche Diagnostics, Basel, Switzerland). Levels of alanine transaminase (ALT) and 
aspartate transaminase (AST) were determined in each sample.  
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4.14 Statistics 
Data were analyzed with Graph Pad Prism 7 software (Graph Pad software, San Diego, CA). T-test to 
compare two variables or one-way ANOVA with Tukey's multiple comparison test for more than two 
variables were used for statistical analysis. The significance threshold was set to p < 0.05. 
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5 Results 
5.1.1 Heme-albumin suppresses IL-1β-induced upregulation of adhesion 
molecules on endothelial cells in vitro 
RT-qPCR 
Quantitative RT-PCR was used to demonstrate the changes in mRNA levels of pro-inflammatory 
adhesion molecules VCAM-1 and E-selectin. We could show a significant suppression of VCAM-1 and 
E-Selectin levels in the heme-albumin+IL-1β (100U/ml) treated HUVEC compared to cells treated 
with IL-1β (100U/ml) alone. The degree of heme-mediated suppression of mRNA expression of 
VCAM-1 and E-selectin was dose-dependent (Fig. 4). There were no significant changes between the 
mRNA levels of VCAM-1 and E-selectin in untreated samples (ctrl) and the samples treated with 
heme-albumin 80 and 160µM. 
 
Figure 4: heme-albumin suppresses upregulation of IL-1β-induced VCAM-1 and E-selectin 
mRNA expression 
Real-time PCR quantification of relative mRNA expression of proinflammatory adhesion molecules 
on HUVEC in response to heme-albumin 80 or 160µM ± human IL-1β 100U/ml vs. IL-1β 100U/ml 
stimulation. Ctrl=untreated cells. Data are shown in triplicates (n=3). Statistical significance (one-
way ANOVA with Tukey's multiple comparison test) is displayed as follows: ***=p<0.001, 
**=p<0.01 
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VCAM-1 In-Cell Western Immunofluorescent Assay  
With the In-cell Western Immunofluorescent Assay, we were able to confirm the results of the 
previous RT-qPCR analysis on protein levels of formaldehyde fixed cells. Namely, we could 
demonstrate the suppression of VCAM-1 protein expression on IL-1 stimulated HUVEC in presence 
of heme-albumin. In the image taken with the infrared imager (LI-COR) (see Fig.5a), we can clearly 
recognize the green signal correlating with IL-1 (100U/ml) mediated VCAM-1 expression. We 
observe a complete suppression of IL-1 response by heme in a dose-dependent manner. Figure 5b 
shows the 800nm/700nm quotient of relative fluorescent units from the same experiment. No signal 
for VCAM-1 expression was observed on cells treated with heme-albumin alone (Fig.5a and b). 
 
Figure 5: heme-albumin suppresses IL-1β induced VCAM-1 expression on HUVEC cell surface 
(a): In-cell Western Immunofluorescent Assay image showing VCAM-1 signal (green) and live-cell 
DNA stain DRAQ5 (red) in response to heme-albumin 80 or 160µM (H80, H160) ± human IL-1β 
100U/ml (IL-1) or IL-1β 100U/ml stimulation. Ctrl=untreated cells. (b) Quantification of VCAM-1 
signal expressed relative to live-cell DNA stain DRAQ5 in relative fluorescence units of the same 
experiment as in (a). Data are shown in octuplicates (n=8). Statistical significance (one-way ANOVA 
with Tukey's multiple comparison test) is displayed as follows: ***=p<0.001 
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5.1.2 Heme-albumin suppresses IL-1β-induced inflammatory chemokine 
release from endothelial cells in vitro 
IL-8 Immunoassay 
To investigate the effect of heme-albumin on chemokine release under inflammatory conditions, we 
measured IL-8 concentrations in HUVEC culture supernatants.  IL-8 secretion of IL-1β stimulated 
HUVEC is significantly (p<0.001) suppressed upon 4h pretreatment with heme-albumin (Fig.6). 
These results show again a dose-dependent effect. Moreover, no IL-8 secretion was observed in cells 
treated with heme-albumin alone. 
 
 
Figure 6: heme-albumin suppresses IL-1β-induced inflammatory chemokine IL-8 release from 
HUVECs 
IL-8 concentrations (conc) in pg/ml measured in Bio-Plex Immunoassay in response to heme-
albumin (heme) 80 or 160µM ± human IL-1β 100U/ml (IL-1) or IL-1β 100U/ml stimulation in HUVEC 
supernatants. Ctrl=untreated cells. Data are shown in octuplicates (n=8). Statistical significance 
(one-way ANOVA with Tukey's multiple comparison test) is displayed as follows: ***=p<0.001 
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Monocyte Adhesion Assay 
Next, we investigated adherence of LPS-activated monocytes to endothelial cells to confirm the 
functional relevance of heme-albumin triggered suppression of IL-8 release and VCAM-1 expression 
upon IL-1β stimulation. Adherence of activated monocytes was maximal to IL-1β stimulated 
HUVEC. Heme-albumin pretreatment causes significant (p<0.001) dose-dependent decrease in 
monocyte adherence to IL-1β activated HUVEC (see Fig.7). HUVEC cells pretreated with heme-
albumin in doses of 80-160µM showed minimal monocyte adhesion. 
 
 
Figure 7: heme-albumin suppresses IL-1β-induced activated monocyte adhesion on HUVEC  
Quantification of LPS-activated and fluorescence-labeled monocyte adhesion to HUVEC, which were 
pretreated with heme-albumin (heme) 80 or 160µM ± human IL-1β 100U/ml (IL-1) or IL-1β 100U/ml stimulation. 
Ctrl=untreated HUVEC. Data display fluorescence units’ measurement at 520nm of treatment  in octuplicates 
(n=8). Statistical significance (one-way ANOVA with Tukey's multiple comparison test) is displayed as follows: 
***=p<0.001  
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5.1.3 Heme-albumin effect on endothelial barrier function 
Electric Cell-substrate Impedance Sensing (ECIS) 
The endothelial barrier function of confluent monolayers of HUVEC were studied before and during 
the treatment with increasing concentrations of heme-albumin. Impedance measurement of all 15 
wells started 8h before treatment. At confluency, when impedance reached a plateau, time point 0 
was set and the impedance was normalized to 1. The cells were stimulated at time point 0 with 0, 40, 
80 or 160µM heme-albumin in triplicates. Impedance was continuously recorded for further 12h (Fig. 
8). The first drop in the normalized impedance in all wells, as seen in Figure 8, at time point 0 is an 
artefact caused by manipulating the well during application of stimuli. 2h after stimulation, the 
impedance levels were balanced back to a constant value. The impedance of untreated and heme-
albumin 40 and 80µM treated cells does not vary significantly over the time recorded (Fig.8). The 
impedance values of the heme-albumin 160µM stimulated cells drop during the first 6h of treatment 
by approximately 50%. Thereafter, the impedance starts to rise again 8h after stimulation. The cell 
impedance of heme-albumin 320uM treated cells decreases already at 2h and remains at very low 
level for the rest of the recorded time (Fig. 8). 
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Figure 8: heme-albumin effect on endothelial barrier function 
HUVEC were grown to confluent monolayers on ECIS 8well chamber slides. Electric cell impedance at 
16kHz over time was measured in triplicates per treatment using ECIS® technology. Impedance was 
normalized to 1 at timepoint 0. HUVECs were stimulated with 0 (ctrl), 40, 80, 160 or 320µM heme-
albumin (heme) at timepoint 0. Data represent means ± SD from 8h before to 12h after stimulation 
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5.1.4 Heme-albumin-induced hypoinflammation in endothelial cells is not 
caused by the impairment of metabolic function 
Extracellular Flux Assay  
To exclude that the above described heme-mediated hypoinflammatory effect on adhesion 
molecule expression, chemokine release and the changes in barrier function shown in ECIS 
experiment are all caused by heme toxicity, we measured mitochondrial function and glycolytic rate 
in heme-albumin treated cells with a XF Cell Mito stress test using a Seahorse extracellular flux 
analyzer, as described in Methods. 
There was no impairment of metabolic function of HUVEC pretreated with heme-albumin 80 or 
160µM for 6h (Fig. 9). The oxygen consumption rate profile (OCR) (Fig. 9a) is similar in untreated 
HUVEC and cells treated with heme-albumin 80µM and heme-albumin 160µM, respectively. 
Likewise, the extracellular acidification rate (ECAR), which measures the proton (H+) production in 
glycolysis after addition of different mitochondrial inhibitors, was constant in the both untreated 
and heme-albumin treated HUVEC (Fig. 9b), excluding heme-mediated toxicity at concentrations 
where a suppressive effect on inflammation was observed.  One representative experiment from the 
experimental series of 3 is shown in Fig. 9.  
Figure 9: heme-albumin effect on metabolic functions of HUVEC 
(a): Extracellular flux analysis of oxygen consumption rate (OCR, pmol/min) of HUVEC treated with 
0, 80 and 160 µM heme-albumin (heme) for 6h. 
(b): Extracellular acidification rate (ECAR, mpH/min) of HUVEC treated with 0, 80 and 160µM 
heme-albumin (heme) over 6h. Every line corresponds to one well with 40’000 cells 
40 
 
5.1.5 Heme-albumin suppresses LPS-induced inflammatory response in 
murine lung endothelial cells in vivo 
RT-qPCR 
VCAM-1 mRNA expression was measured by RT-qPCR as read-out for activation of pro-
inflammatory NFκB pathway in endothelial cells in an LPS-induced inflammation mouse model in 
vivo. As described above, LPS causes activation of leucocytes, especially monocytes. They release 
their typical pro-inflammatory cytokines IL-1β and TNFα and thus activate endothelial cell 
inflammatory response.  We isolated RNA from lung endothelial cells from B6 mice treated with 
heme-albumin 100µmol/kg body weight ± LPS 0.5mg/kg body weight and then performed a RT-
qPCR. As shown in Fig.10, VCAM-1 mRNA expression on lung endothelial cells of LPS-challenged 
animals was significantly suppressed when mice were pretreated with heme-albumin.  
  
Figure 10: heme-albumin suppresses upregulation of LPS induced VCAM-1 mRNA expression on 
lung endothelial cells in wild-type animals in vivo 
Real-time PCR quantification of mRNA expression given as 𝑙𝑙𝑙𝑙𝑙𝑙2−∆𝐶𝐶𝐶𝐶of VCAM-1 on murine LuEC in 
response to 4h LPS 0.5mg/kg body weight ± overnight heme-albumin 100µmol/kg body weight 
pretreatment. Ctrl=untreated animals. Data represent triplicates (n=3). Statistical significance      
(one-way ANOVA with Tukey's multiple comparison test) is displayed as follows: **=p<0.01   
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5.1.6 Heme-albumin rescues anti-CD40-induced necroinflammatory liver 
disease in mouse  
Macroscopic and histological analysis 
To explore the immunomodulatory effect of heme-albumin in anti-CD40 induced 
necroinflammatory liver disease we collected liver lobes from heme-albumin ± anti-CD40 treated B6 
mice. We observed that treatment of animals with agonistic anti-CD40 leads to ischemic liver 
infarctions, which coincide with histological evidence of arterial thrombosis seen in Fig. 12c. In the 
macroscopic image of the liver lobe from an anti-CD40-treated mouse, we see white areas 
corresponding to necrotic zones (Fig.11 b). The macroscopic image of the liver lobe from heme-
albumin + anti-CD40 treated animal, the white areas are not present (Fig. 11 c).  In the 
corresponding histological analysis we can clearly recognize areas of ischemic tissue necrosis with 
perivascular immune cell infiltrations in the anti-CD40 liver image (Fig. 13 c). Moreover, we identified 
the necrotic zones mostly in perivascular regions around numerous thromboses, as seen in detail in 
Fig.13c (*) and in the overview image in Fig.12c(*). Figure 12d and 13d show the typical histologies 
of the liver lobes from heme-albumin and anti-CD40 treated animals, where ischemic necrotic areas 
are missing. The histology of the liver lobes from control and heme-albumin treated animals does 
not show any tissue injury (Fig.12a,b and Fig.13a,b). 
 
 
 
  
Figure 11: heme-albumin rescues anti-CD-40 induced liver necrosis 
(a) Control (b) anti-CD40 10mg/kg body weight (c) heme-albumin 70µM/kg body weight+ anti-CD40 
10mg/kg body weight 
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Figure 12: heme-albumin rescues anti-CD40-induced liver necrosis 
(a) Control (b) heme-albumin 70µM/kg body weight 
(c) anti-CD40 10mg/kg body weight (d) heme-albumin 70µM/kg body weight+ anti-CD40 10mg/kg 
body weight. thrombosis (*), necrosis (x); original magnification, x10. 
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Figure 13: heme-albumin rescues anti-CD40-induced liver necrosis  
(a) Control (b) heme-albumin 70µM/kg body weight 
(c) anti-CD40 10mg/kg body weight (d) heme-albumin 70µM/kg body weight+ anti-CD40 10mg/kg 
body weight. (*) thrombosis, (x) necrosis and immune cell infitrates; original magnification, x10 
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Liver enzymes 
To quantify the extent of ischemic infarctions, we measured levels of the liver enzymes alanine 
transaminase (ALT) and aspartate transaminase (AST) in plasma of mice. As shown in figure 14, 
levels of liver enzymes ALT and AST 24h after anti-CD40 administration are significantly elevated 
compared to untreated animals. The elevation of ALT and AST was significantly reduced in the 
heme-albumin pretreated (heme+ anti-CD40) group (p=0.013 for ALT and p=0.03 for AST) compared 
to anti-CD40 treated animals. Moreover, the levels of ALT and AST in untreated and heme+ anti-
CD40 treated animals showed no significant difference. 
 
 
  
Figure 14: levels of ALT and AST show rescue of anti-CD40-induced liver necrosis after heme-
albumin 
Alanine transaminase (ALT) and aspartate transaminase (AST) plasma levels of wild-type (B6) mice 
treated with heme-albumin 70µM/kg body weight, heme-albumin 70µM/kg body weight + anti-
CD40 10mg/kg body weight or anti-CD40 10mg/kg body weight alone. Ctrl=untreated animal. Data 
represent biological replicates, whereat every dot on the graph represents one animal. Statistical 
significance (one-way ANOVA with Tukey's multiple comparison test) is displayed as follows:              
* =p<0.05 
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5.2 Heme-albumin-mediated hypoinflammation in endothelial cells is 
Hmox-1-independent and related to Nrf2 activation 
Because of its close association to heme and its anti-inflammatory properties, a significant role of 
Hmox-1 in heme-dependent hypoinflammation must be assumed. To study Hmox-1 effect, we used 
inducible Hmox-1 knock-out (UBC cre-ERT2 +/- Hmox-1 flox/flox) mouse model to look at the heme 
effect on endothelial inflammatory response in Hmox-1 free system. Using gene array analysis, we 
aimed to dissect the underlying gene expression pattern behind the effects of heme-albumin on 
HUVEC (data not shown). Heme treatment was characterized by upregulation of the following 
genes; hemoxygenase 1 (Hmox-1), NAD(P)H dehydrogenase [quinone] 1 (NQO1), sodium-
independent cystine-glutamate antiporter (Scl7a11) and glutathione-disulfide reductase (GSR), 
which were identified as Nrf2 target genes [47, 48]. Therefore, we decided to look closer at the role 
of the enzyme Hmox-1 and the transcription factor Nrf2 in the heme-mediated hypoinflammation in 
endothelial cells.  
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5.2.1 Heme-albumin-mediated hypoinflammation is Hmox-1 
independent 
 RT-qPCR 
To investigate a predominant effect of Hmox-1 in the heme-induced suppression of the NFκB-
dependent inflammatory response in vivo, we used UBC cre-ERT2 +/- Hmox-1 flox/flox mice, treated 
them with tamoxifen as described in the method section, and obtained Hmox-1 knock-out animals. 
Thereafter, the mice were treated with heme-albumin 50µmol/kg body weight overnight and 
challenged with LPS 0.5mg/kg body weight for 4h each. As seen in Fig. 15, the LPS induced 
overexpression of VCAM-1 mRNA in murine hmox-ko LuEC is significantly suppressed by heme-
albumin pretreatment. 
 
Figure 15: heme-albumin suppresses upregulation of LPS-induced VCAM-1 mRNA expression on 
lung endothelial cells in hmox-1 knock-out animals in vivo 
Real-time PCR quantification of VCAM-1 mRNA expression, given as 𝑙𝑙𝑙𝑙𝑙𝑙2−∆𝐶𝐶𝐶𝐶 in murine LuEC in 
response to 4h LPS 0.5mg/kg body weight ± overnight heme-albumin 50µmol/kg body weight 
pretreatment. Ctrl=untreated animals. Every data point represents 1 mouse. Data represent 
replicates from 3 experiments. Statistical significance (one-way ANOVA with Tukey's multiple 
comparison test) is displayed as follows: **=p<0.01 
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5.2.2 Heme-albumin causes Nrf2 activation in vitro 
RT-qPCR 
 We performed a RT-qPCR experiment and looked at changes in mRNA expression of the Nrf2 target 
genes NQO1, Slc7a11, GSR and Hmox-1. Our results revealed significant upregulation of all Nrf2-
dependent target genes after heme-albumin treatment compared to untreated controls. Moreover, 
the induction was heme dose-dependent (Fig.16). In detail, NQO1 mRNA expression was 5-fold 
higher in heme 80µM treated (p<0.01), and approx. 7-fold higher in 160µM treated (p<0.001) 
compared to untreated HUVEC. Scl7a11 mRNA expression was approx. 6-fold (80µM; p<0.05) and 9-
fold (160µM; p<0.01) elevated with heme-albumin compared to untreated HUVEC.  GSR mRNA 
levels increased approx. 2-fold (80µM; p<0.05) and 6-fold (160µM; p<0.001) in heme-albumin 
treated compared to untreated HUVEC. Hmox-1 mRNA expression was approx. 70-fold (80µM, not 
significant), and 800-fold (160µM; p<0.05) upregulated in heme-albumin treated cells compared to 
controls. For Hmox-1, (in Fig. 16) 1500-fold change in mRNA expression in one of the 160µM heme-
albumin samples stands clearly out. 20µM RA839 (Nrf2 activator) treated HUVEC were add to the 
experimental system as positive controls for Nrf2 induction. 
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Figure 16: heme-albumin causes Nrf2-activation and upregulation of Nrf2-dependent 
genes in vitro 
RT-qPCR quantification of relative mRNA expression of Nrf2-dependent genes NQO1, 
Scl7a11, GSR and Hmox-1 in HUVEC in response to heme-albumin 80 or 160µM or Nrf-2 
activator RA839 20µM. Ctrl=untreated cells. Data represent triplicates (n=3). Statistical 
significance (one-way ANOVA with Tukey's multiple comparison test) is displayed as 
follows: ***=p<0.001, **=p<0.01, * =p<0.05   
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Nrf2 Translocation Assay 
To explore the Nrf2 activation and its translocation in nucleus, we collected cytoplasmic and nuclear 
fractions of proteins and looked for presence of Nrf2 in the nuclear fraction. As shown in figure 17, 
Nrf2 concentration in nucleic fraction of HUVEC protein lysate is higher in heme-albumin 80µM 
treated cells compared to untreated cells and it is comparable to the Nrf2 concentration in the Nrf2 
activator RA 839 treated cells.  
Hence, heme-albumin enhances nuclear translocation of Nrf2 in HUVEC after 6h of treatment. β-
Actin was used as a loading control on the same membrane as shown in Fig. 17, lower line.  
 
Figure 17: heme-albumin causes Nrf2 translocation in nucleus 
Representative Western blot of nuclear Nrf2 levels in Control, Heme 80µM and Nrf-2 activator RA 
839 20 µM treated HUVEC after 6h of treatment (upper line). β-Actin was used as loading control 
(lower line) 
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5.2.3 Heme-albumin causes Nrf2 activation and upregulation of Nrf2 
target genes in vivo 
RT-qPCR 
To look at Nrf2 activation in vivo, we analyzed samples from our in vivo heme+LPS experiment in 
wild-type mice (same samples as in Fig. 10) for mRNA expression of the Nrf2 target genes Hmox-1 
and Slc7a11.  As shown in Figure 18, we can observe a tendency towards increased Hmox-1 and 
Slc7a11 mRNA expression in heme-albumin pretreated sample. 
 
  
Figure 18: heme-albumin modulation of Nrf2 target gene expression in vivo 
Real-time PCR quantification of mRNA expression given as 𝑙𝑙𝑙𝑙𝑙𝑙2−∆𝐶𝐶𝐶𝐶of Nrf2 target genes Hmox-1 
and Scl7a11 in wild type mice in response to overnight heme-albumin 100µmol/kg body weight ± 4h 
LPS 0.5mg/kg body weight or 4h LPS 0.5mg/kg body weight i.p. treatment. Control=untreated 
animals. Every data point represents 1 mouse. Data represent replicates from 3 experiments  
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6 Discussion 
Until today, the exact role of heme in hemolytic conditions like sickle cell disease, malaria or sepsis is 
not fully understood. Endothelial cells as sentinels for intravascular pathological processes are major 
initiators of immune system responses [14, 18].  Their interaction with free hemoglobin and heme 
and their role in the initiation of inflammatory responses is a key element for understanding why 
intravascular hemolysis causes severe clinical condition. 
6.1 Heme suppresses inflammatory responses in endothelial cells 
Our data indicate a suppressive role of heme on endothelial inflammation. We demonstrated 
suppressive effects of heme-albumin on IL-1β-induced mRNA overexpression of the adhesion 
molecules VCAM-1 and E-selectin in HUVEC in vitro (Fig.4 and 5). Furthermore, we presented heme-
albumin driven suppressive effects on chemokine production by looking at IL-8 release from 
activated endothelial cells (Fig. 6).  Consistent with these data, we observed a significant decrease of 
monocyte adhesion on IL-1 β stimulated HUVEC (Fig. 7). 
By real-time assessment of the barrier function of HUVEC monolayers during stimulation with 
increasing doses of heme-albumin, we could show that endothelial barrier function remains stable 
upon treatment with 40-80µM heme-albumin, deteriorates transiently upon treatment with 160µM 
heme-albumin and permanently upon treatment with 320µM heme-albumin, respectively (Fig. 8). 
To exclude heme-dependent cellular toxicity as a possible reason for heme-induced suppression of 
inflammatory responses and for changes in endothelial barrier function, we demonstrated that the 
mitochondrial function is not impaired by heme-albumin treatment in vitro, especially in cells 
treated with 160µM heme-albumin (Fig. 9).  
We suggest that previous reports of pro-inflammatory effects of heme might have been influenced 
by the difficult biophysical properties of purified (protein-free) heme [49]. For the hydrophobic 
molecule heme, it is very unlikely to occur in considerable quantities in free, monomeric form in 
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plasma because of its tendency to bind to different hemoproteins like hemoglobin and myoglobin, 
or to albumin [5]. Many in vitro experiments suggesting a pro-inflammatory role of heme were 
carried out under serum-free conditions [50-52], where the amount of free, non-protein bound 
heme is much higher than in the serum-enriched medium. Different experiments with heme 
mixtures were previously conducted in our laboratory and the amount of free heme in our heme-
albumin mixture was usually around 10% compared to the standard heme-NaOH mixture, which 
contained around 80% of free heme (data not shown). Therefore, we postulate that heme bound to 
a carrier protein albumin, instead of free heme, corresponds better to the physiological state in 
living organism. 
Heme drives anti-inflammation in lung endothelial cells in LPS-induced 
inflammatory mouse model 
To examine the effect of heme on the endothelial cell immune response in vivo, we used 2 
inflammatory mouse models. First, we demonstrated that heme-albumin suppresses the 
inflammatory response in LPS-induced inflammatory mouse model by showing heme-mediated 
suppression of VCAM-1 expression on murine lung endothelial cells in vivo (Fig. 10). The activation 
of the endothelial inflammatory response might be caused directly by activation of TLR4 by LPS on 
the endothelial cell surface or indirectly by LPS-induced activation of innate immune cells like 
monocytes and their production of pro-inflammatory cytokines IL-1β and TNFα, which activate 
endothelial cells [14, 17].   
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Heme-mediated rescue effect in an anti-CD40 induced ischemic liver 
necrosis mouse model 
A model of necroinflammatory liver disease caused by administration of an agonistic monoclonal 
antibody anti-CD40 in mice was reported, and a pivotal role of B-cell and macrophage induced TNFα 
and INFγ in this model was described [24]. However, the exact mechanism of necrosis development 
and the role of vascular endothelial cells in this model remained ambiguous.  
Here we report a novel observation that heme provides rescue from anti-CD40 induced 
necroinflammatory liver disease. As shown in Fig. 11b and 12c, single administration of anti-CD40 to 
mice causes development of extensive necrotic areas throughout the liver tissue. Remarkably, we 
identified the necrosis areas mostly in perivascular regions and discovered numerous thromboses in 
the vessels surrounded by necrotic zones (Fig 12c and 13c). Heme challenge suppresses the 
phenotype of the disease as suggested by the absence of necrotic lesions (Fig. 11c, 12-13d) and the 
pronounced decrease of transaminase levels (Fig. 14).  
The limitation of these in vivo data is the overall small number of animals and the uneven number of 
data points per each treatment group. This fact was due to limited number of available animals and 
due to technical limitations of our blood collection method. These data represent single experiment 
from our experimental series and can therefore support our hypothesis, but not definitely prove the 
heme rescue effect on anti-CD40 induced liver necrosis. Further experiments are already ongoing 
and may provide additional evidence for our hypothesis in the near future. 
In summary, the anti-CD40 related findings support our previous results that heme has an anti-
inflammatory effect, and show that heme can prevent anti-CD40 dependent necroinflammatory 
liver injury. Nonetheless, several questions remain open and need to be discussed.  
First, the role of endothelial cells and their interaction with the immune cells in the described anti-
CD40 induced necroinflammatory desease has to be proven by future research. The observation of 
thrombosis in the liver vasculature after anti-CD40 administration provides a strong sign that 
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endothelial cell activation may be involved in the pathogenesis of  this disease model. The role of 
macrophages in the anti-CD40 induced liver disease was demonstrated in previous studies [21, 24]. 
Inflammatory cytokines, especially TNFα and INFγ, and chemokine release from macrophages are 
believed to be the central mechanisms in development of  necrotic liver damage and are well known 
to cause endothelial cell activation [24]. Therefore, we postulate that anti-CD40 activated 
macrophages cause TNFα and INFγ triggered endothelial cell activation, which can be reversed by 
heme. The fact that endothelial cells themselves express CD40 receptor, rises a second hypothesis 
that endothelial cells may as well get directly activated by anti-CD40 in the blood stream and that 
this activation can be supressed by heme priming [53]. 
Second, the mechanism behind the heme anti-inflammatory effect has still to be cleared and  will be 
discussed in the following chapter.  
6.2 Mechanisms involved in the suppressive effect of heme on the 
endothelial inflammatory response 
Heme-driven hypoinflammation is Hmox-1 independent 
Hmox-1, as one of the pivotal enzymes of anti-inflammation and anti-oxidation, is the major, rate-
limiting enzyme in heme degradation [6]. To elucidate the dependence of heme-driven 
hypoinflammation on Hmox-1, we compared the role of heme in a LPS-induced inflammation 
mouse model in wild type and Hmox-1 knock-out animals. Interestingly, the heme-mediated 
suppressive effect on the endothelial inflammatory response in murine LuEC remained unchanged 
in Hmox-1 knock-out mice (Fig. 15) compared to the heme-mediated hypo-inflammatory effect on  
LuEC from wild-type mice (Fig. 10). Our results suggest that heme-dependent hmox-1 upregulation, 
which is described as the major protective anti-inflammatory and anti-oxidative cellular pathway [6], 
is not the main player driving the heme-dependent anti-inflammation observed. 
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Heme activates transcription factor Nrf2  
To elucide the mechanism behind heme-driven hypoinflammation in endothelial cells, gene array 
experiments on HUVEC were conducted in our laboratory (data not shown). We observed heme-
driven upregulation of Hmox-1, NQO1 and Scl7a11 genes, which share a common transcription 
factor Nrf2 [26].  Nrf2 is well known for its anti-oxidant and anti-inflammatory role and therefore we 
decided to investigate the involvement of Nrf2 in heme-driven hypoinflammation [27] .  
First, we confirmed mRNA upregulation of the Nrf2 dependent genes NQO1, Scl7a11, GSR, and 
Hmox-1, and accumulation of Nrf2 protein in nuclear fractions of HUVEC upon heme stimulation 
(Fig. 16 and 17). Next, preliminary in vivo data on wild-type murine lung endothelial cells point to a 
tendency in heme-dependent mRNA upregulation of Nrf2 target genes Scl7a11 and Hmox-1 (Fig. 
18). To reach statistical significance in these in vivo experiments with wide data point variance 
within a treatment group, further experiments with more animals are necessary. The dose-
dependent upregulation of Nrf2 target genes in vitro and in vivo and the nucleic accumulation of 
Nrf2 protein upon heme-albumin treatment in vitro indicate a strong heme/Nrf2 interaction. To 
definitively proof the Nrf2 dependency of heme-mediated hypoinflammation, a Nrf2 knock-out 
model would be needed.     
Further, the preserved supression of VCAM-1 expression by heme pre-stimulation in lung 
endothelial cells from Hmox-1 knock-out mice (Fig. 15) support the above mentioned theory of 
Kobayashi, that the Nrf2 anti-inflammatory effect is independent from its anti-oxidant pathway [9] 
and that  heme acts via Nrf2 anti-inflammatory pathway independently  from Hmox-1 .   
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6.3 Conclusions 
Taken together, in this study we proved our hypothesis that heme causes suppression of 
inflammatory responses on endothelial cells. We showed heme-induced suppression of pro-
inflammatory NFκB dependent adhesion molecules VCAM-1 and E-Selectin, and the chemokine IL-
8. We could demonstrate for the first time that the suppressive effects on endothelial inflammation 
were related to heme itself and not to Hmox-1 expression. Furthermore, we could identify heme-
mediated Nrf2 activation as a potential driver of hypoinflammation in endothelial cells.  
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